Tirzepatide to prevent atrial fibrillation return after ablation in obesity
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether a weight-loss medication called tirzepatide (given as a shot) helps prevent atrial fibrillation from coming back after a catheter ablation procedure. It is for people who have both obesity and atrial fibrillation, and it may help improve heart health by reducing weight and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have symptomatic atrial fibrillation (irregular heartbeat) that is either paroxysmal (comes and goes) or persistent (lasts more than 7 days), with a total history of AF of 5 years or less.
- You have a body mass index (BMI) of 28 or higher, or a BMI of 24 or higher with at least one weight-related condition like high blood pressure, high cholesterol, diabetes, sleep apnea, or heart disease.
- You have had an unsuccessful response to at least one antiarrhythmic drug, or you prefer a strategy to control your heart rhythm.
- You are scheduled to undergo catheter ablation for AF at a participating center, and the procedure must successfully restore a normal heart rhythm.
- You are willing to participate in follow-up visits for up to 12 months and able to perform basic physical activity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a weekly injection of tirzepatide (a medicine that helps with weight loss and blood sugar) can lower the chance of atrial fibrillation coming back after a heart procedure called catheter ablation. It may help people who are overweight or have obesity and are having this procedure.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the heart rhythm condition atrial fibrillation. If you have AFib and are overweight or obese, this trial may be an option for you.
This study tests whether tirzepatide (a weekly injection for weight loss and diabetes) can prevent atrial fibrillation from coming back after catheter ablation, in people with obesity and heart failure with preserved ejection fraction. It may help by reducing weight and improving heart function.
This study looks at whether losing weight can help reduce the progression of atrial fibrillation (an irregular heartbeat). It might help people who are overweight and have AF symptoms.
This study tests whether the medicine tirzepatide can help adults who are overweight or obese and have congenital heart disease (a heart condition present from birth) lose weight safely. The medicine may also improve heart health and metabolism. It is for people who have already tried diet and exercise for at least a year without much weight loss.
This trial tests whether a weight loss medication (semaglutide) given before and after a first-time heart ablation procedure for atrial fibrillation can improve outcomes. It is for people who are overweight or obese and have certain related health conditions.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.